Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Thermo Fisher To Dominate Transplant Dx Market With $925 Million One Lambda Purchase

This article was originally published in The Gray Sheet

Executive Summary

Deal gives Thermo broad access to $480 million global transplant diagnostics market, a segment growing at a mid- to high-single-digit percentage rate.

You may also be interested in...



News In Brief

Thermo Fisher acquires Life Technologies. Mako acquires Stanmore Implants as part of a settlement between the robot-makers. More news.

Device/Diagnostics Quarterly Deal Statistics, Q3 2012

Device companies raised a total of $801 million in 2012’s third quarter, an 18% drop from Q2’s $977 million. Approximately $2.6 billion was spent on device acquisitions, exactly $2 billion less than Q2’s total. Diagnostic/research company financings totaled $484 million during Q3 2012, up from last quarter’s $336 million. And while diagnostic/research M&A activity was not as prolific as last quarter, tech transfer deals are seeing a resurgence.

Thermo Fisher Underscores Allergy Test Opportunity With $3.5 Bil. Phadia Deal

Thermo Fisher Scientific wants to claim a dominant share of the budding in vitro allergy testing market segment in the U.S. with its planned $3.5 billion acquisition of Swedish firm Phadia, announced May 19.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT031418

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel